These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131 [TBL] [Abstract][Full Text] [Related]
12. Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives. Smith HM; Knox AJ; Zisterer DM; Lloyd DG; Meegan MJ Med Chem; 2007 Mar; 3(2):135-55. PubMed ID: 17348852 [TBL] [Abstract][Full Text] [Related]
13. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties. Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841 [TBL] [Abstract][Full Text] [Related]
14. 2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity. von Angerer E; Strohmeier J J Med Chem; 1987 Jan; 30(1):131-6. PubMed ID: 3806590 [TBL] [Abstract][Full Text] [Related]
15. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms. Jain N; Xu J; Kanojia RM; Du F; Jian-Zhong G; Pacia E; Lai MT; Musto A; Allan G; Reuman M; Li X; Hahn D; Cousineau M; Peng S; Ritchie D; Russell R; Lundeen S; Sui Z J Med Chem; 2009 Dec; 52(23):7544-69. PubMed ID: 19366247 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor ligands. Part 4: The SAR of the syn-dihydrobenzoxathiin SERAMs. Kim S; Wu J; Chen HY; Birzin ET; Chan W; Yang YT; Colwell L; Li S; Dahllund J; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML Bioorg Med Chem Lett; 2004 Jun; 14(11):2741-5. PubMed ID: 15125925 [TBL] [Abstract][Full Text] [Related]
17. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats. Hummel CW; Geiser AG; Bryant HU; Cohen IR; Dally RD; Fong KC; Frank SA; Hinklin R; Jones SA; Lewis G; McCann DJ; Rudmann DG; Shepherd TA; Tian H; Wallace OB; Wang M; Wang Y; Dodge JA J Med Chem; 2005 Nov; 48(22):6772-5. PubMed ID: 16250633 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, pharmacological evaluation, and structure-activity relationships of benzopyran derivatives with potent SERM activity. Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M; Caruso PL; Galbiati E; Lipreri M; Rivara S; Lodola A; Mor M Bioorg Med Chem; 2004 Jul; 12(14):3763-82. PubMed ID: 15210143 [TBL] [Abstract][Full Text] [Related]
19. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Crabtree JS; Peano BJ; Zhang X; Komm BS; Winneker RC; Harris HA Mol Cell Endocrinol; 2008 Jun; 287(1-2):40-6. PubMed ID: 18367319 [TBL] [Abstract][Full Text] [Related]
20. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue. Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]